WeVote
Log In

Bill

Bill

A 3047

Requires certain notice when redirecting consumers to website for ticket resale and establishes certain requirements for websites offering tickets for resale.

2024-2025 Regular Session Introduced by Clinton Calabrese and 3 co-sponsors

New Jersey bill requires ticket resale websites to disclose when redirecting consumers to resale platforms and establishes operational standards for secondary ticket market transparency.

Introduced in the Assembly, Referred to Assembly Consumer Affairs Committee
#consumerpro
0
WeVote Research Nonpartisan
Bill Summary · A 3047

Legislative bill overview

Bill A 3047 mandates that ticket resellers provide clear notice to consumers when redirecting them to resale websites and establishes operational requirements for ticket resale platforms. The bill aims to increase transparency in the secondary ticket market by ensuring consumers know they are purchasing resold tickets rather than primary market tickets.

Why is this important

The secondary ticket market has grown substantially, but consumers often encounter confusing purchasing experiences where resale sites are presented without adequate disclosure. This bill addresses consumer protection concerns by requiring upfront notification and setting standards for resale platforms, potentially reducing fraud and deceptive practices in a market worth billions annually.

Potential points of contention

  • Business impact on resale platforms: Resellers and ticket resale websites may argue that additional notice requirements and compliance measures increase operational costs and create competitive disadvantages compared to primary ticket vendors.
  • Definition and scope ambiguity: The bill's language around "certain notice" and "certain requirements" lacks specificity, potentially creating confusion about what exactly resellers must disclose and what constitutes compliance.
  • Free market concerns: Some stakeholders may contend that government-mandated disclosures in the resale market interfere with normal commercial transactions and market efficiency without clear evidence of widespread harm.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.